Rote W E, Nedelman M A, Mu D X, Manley P J, Weisman H, Cunningham M R, Lucchesi B R
Dept of Pharmacology, University of Michigan Medical School, Ann Arbor 48108-0626.
Stroke. 1994 Jun;25(6):1223-32; discussion 1233. doi: 10.1161/01.str.25.6.1223.
We compared the current antithrombotic strategy of antiplatelet therapy with aspirin, and anticoagulant therapy with heparin, with a specific genetically engineered chimeric antibody (c7E3 Fab) directed against the human glycoprotein IIb/IIIa receptor in an animal model of arterial thrombosis.
Anesthetized cynomolgus monkeys (Macaca fascicularis) were instrumented for monitoring of arterial blood pressure, heart rate, and carotid artery flow velocity. Animals were treated with saline (n = 6), aspirin (25 mg PO daily for 3 days; n = 6), heparin (100 U/kg i.v. plus infusion adjusted to maintain activated partial thromboplastin time at 2 to 3 times baseline; n = 6), aspirin plus heparin (as administered separately, n = 6), or c7E3 Fab (0.10 mg/kg i.v., n = 7; 0.15 mg/kg i.v., n = 6; 0.20 mg/kg i.v., n = 6; 0.25 mg/kg i.v., n = 6). Thrombus formation via anodal electrolytic stimulation (100 microA) to the intimal surface of the right carotid artery was initiated 15 minutes after drug administration and continued for 180 minutes. Electrolytic injury to the left carotid artery began 210 minutes after drug administration and continued for 180 minutes. Whole blood cell counts, glycoprotein IIb/IIIa receptor blockade, ex vivo platelet aggregation, template bleeding time, and activated partial thromboplastin time were assessed at various time points throughout the experimental protocol.
Hemodynamic and hematologic parameters were comparable among groups at baseline. Treatment with c7E3 Fab inhibited ex vivo platelet aggregation, increased bleeding time, decreased thrombus weight, and increased time to occlusion in a dose-dependent manner in both vessels. Treatment with aspirin, heparin, or the combination of aspirin plus heparin was ineffective for the prevention of carotid artery thrombosis in this model.
Inhibition of the platelet glycoprotein IIb/IIIa receptor with c7E3 Fab was found to be safe and effective for the prevention of primary thrombus formation, whereas treatment with either aspirin or heparin or the combination of the two agents failed to protect against occlusive thrombus formation in cynomolgus monkeys.
我们在动脉血栓形成的动物模型中,将当前使用阿司匹林的抗血小板治疗策略以及使用肝素的抗凝治疗策略,与一种针对人糖蛋白IIb/IIIa受体的特定基因工程嵌合抗体(c7E3 Fab)进行了比较。
对麻醉的食蟹猴(猕猴)进行仪器安装,以监测动脉血压、心率和颈动脉血流速度。动物分别接受生理盐水治疗(n = 6)、阿司匹林治疗(每日口服25 mg,共3天;n = 6)、肝素治疗(静脉注射100 U/kg,加持续输注以维持活化部分凝血活酶时间为基线的2至3倍;n = 6)、阿司匹林加肝素治疗(分别给药,n = 6)或c7E3 Fab治疗(静脉注射0.10 mg/kg,n = 7;0.15 mg/kg,n = 6;0.20 mg/kg,n = 6;0.25 mg/kg,n = 6)。给药15分钟后,通过对右颈动脉内膜表面进行阳极电解刺激(100 μA)启动血栓形成,并持续180分钟。给药210分钟后开始对左颈动脉进行电解损伤,并持续180分钟。在整个实验过程中的不同时间点评估全血细胞计数、糖蛋白IIb/IIIa受体阻断情况、体外血小板聚集、模板出血时间和活化部分凝血活酶时间。
各实验组在基线时的血流动力学和血液学参数具有可比性。c7E3 Fab治疗以剂量依赖方式抑制体外血小板聚集、延长出血时间、减轻血栓重量并增加血管闭塞时间。在该模型中,阿司匹林、肝素或阿司匹林加肝素联合治疗对预防颈动脉血栓形成无效。
发现用c7E3 Fab抑制血小板糖蛋白IIb/IIIa受体对预防原发性血栓形成安全有效,而阿司匹林、肝素或二者联合治疗均未能预防食蟹猴的闭塞性血栓形成。